FDA Drug Recalls

Recalls / Class II

Class IID-0825-2018

Product

Loxapine Capsules, USP 50 mg, Rx Only, 100-count bottles, NDC 0378-7050-01

Affected lot / code info
NDC 0378-7050-01 Lot Numbers: 3079386, Exp. 10/31/18 3079387, Exp. 10/31/18 3079388, Exp. 10/31/18 3083762, Exp. 3/31/19 3083763, Exp. 3/31/19 3083764, Exp. 3/31/19 3083765, Exp. 3/31/19 3083766, Exp. 3/31/19 3083767, Exp. 3/31/19

Why it was recalled

CGMP Deviations

Recalling firm

Firm
Mylan Pharmaceuticals Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
781 Chestnut Ridge Rd, N/A, Morgantown, West Virginia 26505-2730

Distribution

Quantity
11,650 bottles
Distribution pattern
Product was distributed throughout the United States, including Puerto Rico.

Timeline

Recall initiated
2018-04-24
FDA classified
2018-05-22
Posted by FDA
2018-05-30
Terminated
2019-08-14
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0825-2018. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: drug · FDA Drug Recalls